Literature DB >> 11603614

The prevalence of multiple sclerosis in the world: an update.

G Rosati1.   

Abstract

The systematic study of multiple sclerosis (MS) in populations, started in 1929 by Sydney Allison, now consists of over 400 publications dealing with the prevalence of MS throughout the world. However, any attempt to redefine the pattern of geographical differences in MS frequency remains as difficult as ever. The comparison of prevalence studies carried out in different areas and times is made difficult by the variability in surveyed population sizes, age structures, ethnic origins and composition, and the difficult quantification of numerators, especially regarding the recognition of benign and very early cases. Additionally, complete case ascertainment depends on access to medical care, local medical expertise, number of neurologists, accessibility and availability of new diagnostic procedures, the degree of public awareness about MS, and the investigators' zeal and resources. Critical examination of the more recent data on MS prevalence leads to some revisions of previously held concepts, the most interesting of which is the appreciation of the greater influence of genetic factors on disease acquisition. The rarity of MS among Samis, Turkmen, Uzbeks, Kazakhs, Kyrgyzis, native Siberians, North and South Amerindians, Chinese, Japanese, African blacks and New Zealand Maoris, as well as the high risk among Sardinians, Parsis and Palestinians, clearly indicate that the different susceptibilities of distinct racial and ethnic groups are an important determinant of the uneven geographic distribution of the disease. The updated distribution of MS in Europe, showing many exceptions to the previously described north-south gradient, requires more explanation than simply a prevalence-latitude relationship. Prevalence data imply that racial and ethnic differences are important in influencing the worldwide distribution of MS and that its geography must be interpreted in terms of the probable discontinuous distribution of genetic susceptibility alleles, which can however be modified by environment. Because the environmental and genetic determinants of geographic gradients are by no means mutually exclusive, the race versus place controversy is, to some extent, a useless and sterile debate.

Entities:  

Mesh:

Year:  2001        PMID: 11603614     DOI: 10.1007/s100720170011

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  141 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

Review 2.  ACS chemical neuroscience molecule spotlight on gilenya (fingolimod; FTY720).

Authors:  Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2011-03-16       Impact factor: 4.418

Review 3.  Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions.

Authors:  Jean-Luc Dreyer
Journal:  Mol Biotechnol       Date:  2011-02       Impact factor: 2.695

Review 4.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

Review 5.  The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders.

Authors:  Jesse Costales; Alexander Kolevzon
Journal:  Neurosci Biobehav Rev       Date:  2016-01-15       Impact factor: 8.989

Review 6.  Multiple Sclerosis in Latin Americans: Genetic Aspects.

Authors:  Victor M Rivera
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08       Impact factor: 5.081

Review 7.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

8.  Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations.

Authors:  Oivind Torkildsen; Egil Utsi; Svein Ivar Mellgren; Hanne F Harbo; Christian A Vedeler; Kjell-Morten Myhr
Journal:  Immunology       Date:  2005-07       Impact factor: 7.397

9.  Absence of the tag polymorphism for the risk haplotype HLA-DR2 for multiple sclerosis in Wixárika subjects from Mexico.

Authors:  G V González-Enríquez; B M Torres-Mendoza; J Márquez-Pedroza; M A Macías-Islas; G G Ortiz; J A Cruz-Ramos
Journal:  Immunogenetics       Date:  2018-02-03       Impact factor: 2.846

Review 10.  Demyelinating diseases.

Authors:  S Love
Journal:  J Clin Pathol       Date:  2006-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.